Elan and Transition Therapeutics Drug: ELND-005 Drug type: Amyloid beta Stage: Phase II On Aug. 9, Elan and Transition announced plans to move ELND-005 into phase III studies despite what appears to be mixed results from a recently completed phase II study in mild to moderate Alzheimer's patients. The phase II study of ELND-005 failed to meet its cognitive and functional endpoints overall but the companies said the drug had an effect on amyloid-beta proteins in the spinal fluid and showed some clinical benefit in a subgroup of patients. Eli Lilly Drug: Solanezumab Drug type: Amyloid beta immunotherapy Stage: Phase III Two phase III studies of solanezumab are currently enrolling patients with mild to moderate Alzheimer's patients. Results are expected in 2012-2013. Bristol-Myers Squibb ( BMY) Drug: BMS-708163 Drug type: Gamma secretase inhibitor Stage: Phase II BMS-708163 belongs to the same class of gamma secretase inhibitors as Lilly's discontinued drug semagacestat. Top-line results from the ongoing phase II study of '708163 in patients with mild to moderate Alzheimer's are expected in the fourth quarter. Baxter ( BAX) Drug: Gammagard Drug type: Amyloid Beta Stage: Phase III Baxter expects to complete enrollment in the phase III Gammagard study by the end of the year, with results likely in 2012. The phase III study hopes to confirm positive results seen in phase II studies of Gammagard.